Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 tria-MedSci.cn

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 tria

West, H; McCleod, M; Hussein, M; Morabito, A; Rittmeyer, A; Conter, HJ; Kopp, HG; Daniel, D; McCune, S; Mekhail, T; Zer, A; Reinmuth, N; Sadiq, A; Sandler, A; Lin, W; Lohmann, TO; Archer, V; Wang, LJ; Kowanetz, M; Cappuzzo, F

Cappuzzo, F (reprint author), AUSL Romagna, Dept Hematol & Oncol, I-48100 Ravenna, Italy.

Abstract

Background Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previous......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 tria

科室

工具

服务